Brepocitinib Overview & RVT-3101 Update
IMVT-1402 is designed to deliver maximum IgG reduction while minimizing
impact to LDL levels
Albumin
IgG concentration (mg/mL),
mean percent change from baseline ± SD
100 Similar, maximum IgG reduction
as batoclimab
50
-50
Batoclimab
60
FcRn
Batoclimab
Albumin
IMVT-1402: Head-to-Head Monkey Study
Albumin concentration (g/L),
mean ± SD
Similar albumin impact as placebo
50
I =
干[
H
40
30
6
ULN
5
4
3
LLN
2
20
-100
↑
1
10
0
7
14 21 28
35
42
56
-12
7
14 21
28
35 42
49
56
Day
Day
roivant
Batoclimab 50 mg/kg (n=3)
IMVT-1402 50 mg/kg (n=7)
1
Cholesterol concentration (mmol/L),
mean ± SD
Similar cholesterol impact as placebo
IMVT-1402
3
FcRn
IMVT-1402
LDL concentration (mmol/L),
mean ± SD
Similar LDL impact as placebo
I
H
1
01
1
t
-12
7 14 21
28
35 42
49
56
-12
7
14 21 28 35 42 49 56
Day
Day
IMVT-1402 5 mg/kg (n=7)
Placebo (n=3)
Dose administration
23
Note: Ribbon representations generated from X-Ray crystal structure. Batoclimab solved at 2.4Å resolution. IMVT-1402 solved at 2.6Å resolution.
For investor audiences onlyView entire presentation